MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,198,430K
Free Cash flow
$139,293K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from borrowings
Depreciation and amortization
Stock-based compensation
Others
Negative Cash Flow Breakdown
Acquisition of amicus, net of ca...
G&a expenses
Cost of sales
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
989,708
766,208
874,565
776,133
Cost of sales
202,795
194,999
275,709
140,085
R&d expenses-Research And Early Pipeline
85,069
87,291
103,547
93,720
R&d expenses-Later Stage Clinical Programs
50,295
36,177
29,260
251,650
R&d expenses-Marketed Products
71,588
55,328
59,606
64,108
S&m expenses
142,186
124,927
174,198
131,327
G&a expenses
253,363
133,363
272,009
137,088
Other segment expense, net
139,650
28,596
6,809
-11,101
Net income
44,762
105,527
-46,573
-30,744
Depreciation and amortization
97,638
16,411
20,438
18,487
Non-cash interest expense
21,826
6,086
653
649
Accretion of discount on investments
-
455
1,106
978
Stock-based compensation
75,694
43,458
46,913
49,265
Gain on sale of nonfinancial assets
-
-
0
0
Impairment of assets
0
0
122,045
0
Acquired in-process research & development expense
-
-
0
220,963
Roctavian inventory write-off
-
-
119,208
-
Deferred income taxes
-6,959
9,220
613
-13,646
Unrealized foreign exchange gains
10,756
-6,710
-4,215
-5,550
Other
160
5,374
2,710
-212
Accounts receivable, net
38,846
7,159
120,676
-48,746
Inventory
32,156
-44,490
18,133
26,334
Other current assets
12,038
11,551
-41,016
17,033
Other assets
-7,521
-1,484
5,894
19,174
Accounts payable and accrued liabilities
23,165
3,100
-53,342
116,367
Other long-term liabilities
-2,037
8,704
-7,023
16,355
Net cash provided by operating activities
168,109
220,651
99,644
368,685
Purchases of property, plant and equipment
28,816
20,923
40,722
28,447
Maturities and sales of investments
0
767,277
43,254
98,809
Purchases of investments
0
25,792
42,613
110,829
Proceeds from sale of nonfinancial assets
-
-
0
0
Purchase of intangible assets
5,433
-
2,368
5,303
Acquisition of amicus, net of cash acquired
5,067,630
-
0
285,193
Other
0
-4,966
0
0
Net cash used in investing activities
-5,101,879
725,528
-42,449
-330,963
Proceeds from exercises of awards under equity incentive plans
6,655
-
6,746
7
Taxes paid related to net share settlement of equity awards
11,324
28,180
2,700
2,176
Payments of contingent consideration
0
-
-
-
Repayments of convertible debt
-
-
0
0
Proceeds from borrowings
2,800,000
850,000
-
-
Other
-
-
-889
0
Payments of debt issuance costs
56,951
8,653
-
-
Net cash provided by (used in) financing activities
2,738,380
813,167
3,157
-2,169
Effect of exchange rate changes on cash
-3,040
1,410
1,219
739
Net increase (decrease) in cash and cash equivalents
-2,198,430
1,760,756
61,571
36,292
Beginning of period
3,072,435
1,311,679
1,250,108
942,842
End of period
874,005
3,072,435
1,311,679
1,250,108
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Total revenues
$989,708K
(19.91%↑ Y/Y)
Proceeds from borrowings
$2,800,000K
Depreciation and
amortization
$97,638K
(425.98%↑ Y/Y)
Stock-based compensation
$75,694K
(59.25%↑ Y/Y)
Proceeds from exercises
of awards under...
$6,655K
(-13.65%↓ Y/Y)
Net income
$44,762K
(-81.39%↓ Y/Y)
Accounts payable and
accrued liabilities
$23,165K
(301.75%↑ Y/Y)
Non-cash interest
expense
$21,826K
(3206.97%↑ Y/Y)
Other assets
-$7,521K
(-163.30%↓ Y/Y)
Canceled cashflow
$944,946K
Net cash provided by
(used in) financing...
$2,738,380K
(59591.20%↑ Y/Y)
Net cash provided by
operating activities
$168,109K
(-9.26%↓ Y/Y)
Canceled cashflow
$68,275K
Canceled cashflow
$102,952K
G&a expenses
$253,363K
(129.96%↑ Y/Y)
Cost of sales
$202,795K
(35.12%↑ Y/Y)
S&m expenses
$142,186K
(16.45%↑ Y/Y)
Other segment
expense, net
$139,650K
(238.95%↑ Y/Y)
R&d
expenses-Research And Early...
$85,069K
(-11.36%↓ Y/Y)
R&d
expenses-Marketed Products
$71,588K
(37.12%↑ Y/Y)
R&d expenses-Later
Stage Clinical...
$50,295K
(282.97%↑ Y/Y)
Net increase
(decrease) in cash and cash...
-$2,198,430K
(-1432.28%↓ Y/Y)
Canceled cashflow
$2,906,489K
Payments of debt issuance
costs
$56,951K
Taxes paid related to
net share...
$11,324K
(-8.01%↓ Y/Y)
Accounts receivable, net
$38,846K
(-60.58%↓ Y/Y)
Inventory
$32,156K
(-33.19%↓ Y/Y)
Other current assets
$12,038K
(37.34%↑ Y/Y)
Unrealized foreign
exchange gains
$10,756K
(327.88%↑ Y/Y)
Deferred income taxes
-$6,959K
(-120.87%↓ Y/Y)
Other long-term
liabilities
-$2,037K
(-158.74%↓ Y/Y)
Other
$160K
(-75.35%↓ Y/Y)
Net cash used in
investing activities
-$5,101,879K
(-40416.83%↓ Y/Y)
Effect of exchange rate
changes on cash
-$3,040K
(0.75%↑ Y/Y)
Acquisition of amicus, net of
cash acquired
$5,067,630K
Purchases of property,
plant and equipment
$28,816K
(68.50%↑ Y/Y)
Purchase of intangible
assets
$5,433K
(1942.48%↑ Y/Y)
Buy us a coffee
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)